Mesenchymal stem cell-based therapy for type 1 & 2 diabetes mellitus patients: a systematic review and meta-analysis of randomized controlled trials
Muataz Kashbour, Abubaker Abdelmalik, Mazen Negmeldin Aly Yassin, Mohamed Abed, Ebtesam Aldieb, Duha Milad Abdullah, Taher Elmozugi, Yosser S. Isawi, Eman M. Hassan, Fakhruddin Almuzghi
Abstract
OBJECTIVE: To systematically and statistically evaluate evidence from randomized controlled trials (RCTs) investigating the efficacy and safety of somatic stem cells in achieving glycemic control in type 1 and 2 diabetic patients. METHODS: Bibliographic databases including PubMed, Scopus, Web of Science, and Cochrane Library were searched from the time of their establishment till January 2024. Obtained records were meticulously screened by title, abstract, and full text to include only RCTs seeking mesenchymal stem cells (MSCs) treatment for type 1 diabetes mellitus (T1DM) and 2 diabetes mellitus (T2DM). Included studies underwent quality assessment using the Cochrane risk of bias 2 tool (ROB2). RESULTS: = 81% at the end of the 12-month follow-up. CONCLUSION: Mesenchymal stem cell-derived therapy is an efficacious glycemia-lowering modality agent compared to conventional therapy in T1DM and T2DM patients. Albeit more sizeable and longer RCTs are warranted to further support and standardize their clinical use.